AUS
NZ
UK
CA
USA
IND
Highlights
Mayne Pharma shares advanced as Cosette Pharmaceuticals has not yet withdrawn its takeover offer
The company addressed FDA concerns that were previously flagged as material by Cosette
Takeover developments come amid broader activity on the ASX 200
Mayne Pharma Group Limited (ASX:MYX), listed on the ASX 200 index, operates in the pharmaceutical sector. The company experienced an increase in its share price following updates around the proposed acquisition by US-based Cosette Pharmaceuticals. This activity placed MYX among the more closely watched healthcare stocks during the trading session.
Cosette Pharmaceuticals Yet to Terminate Deal
Mayne Pharma confirmed it has not received any formal termination from Cosette Pharmaceuticals regarding the previously announced takeover proposal. While Cosette retains the right to end the agreement under the scheme implementation deed, no such decision has been formally executed. This comes after the lapse of a mandatory consultation period triggered by Cosette’s concerns over material adverse events.
The Australian-listed firm has maintained that it has not identified any basis for Cosette’s concerns and continues to assert its position under the terms of the agreement. Mayne Pharma noted that it expects the other party to continue progressing with regulatory procedures, including seeking approval from the Foreign Investment Review Board.
FDA Concerns Reportedly Resolved
In the same exchange announcement, Mayne Pharma disclosed that it had received formal correspondence from the US Food and Drug Administration (FDA), confirming that prior concerns raised by the regulator have now been addressed. These concerns were initially referenced by Cosette as part of its hesitation around the deal.
The FDA had previously issued a letter related to promotional activities around Mayne Pharma’s oral contraceptive, Nextstellis. The company had consistently maintained that these concerns were not materially significant. The updated communication from the FDA appears to have closed that matter, according to Mayne’s statement.
Share Price Response Following Corporate Update
Following the latest announcement, shares in Mayne Pharma showed movement during the trading session. Although the share price remains below the indicative takeover price proposed by Cosette, the market reacted positively to the news that the deal has not yet been formally terminated.
Market watchers continue to monitor developments closely as the situation progresses, particularly in light of the remaining regulatory milestones. Under the terms of the scheme deed, Cosette still holds discretion to end the proposal prior to the second court hearing.
Mayne Pharma’s latest update places it in focus on the ASX 200 amid broader corporate activity within the healthcare sector. Investors and industry participants will likely remain attentive to any further developments concerning the status of the proposed acquisition.
